Phase II of Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the objective response rate for the combination of carboplatin, paclitaxel and temozolomide in the treatment of metastatic or recurrent melanoma.
6months
Yes
Montasur Shaheen, MD
Principal Investigator
University of New Mexico
United States: Institutional Review Board
INST 0903
NCT01009515
August 2009
August 2015
Name | Location |
---|---|
University of New Mexico Cancer Center | Albuquerque, New Mexico 87131-5636 |
Hematology Oncology Associates | Albuquerque, New Mexico 87106 |
The Cancer Center at Presbyterian | Albuquerque, New Mexico 87110 |